Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048150 | 0.93 | CTSK (0.47) | CTSK | |
| SCHEMBL4043349 | 0.93 | CTSK (0.49) | CTSKNAMPTSMYD3TP53SMN1; SMN2 | |
| SCHEMBL4040649 | 0.90 | CTSK (0.42) | CTSKSMYD3ACEGPR132 | |
| SCHEMBL4044478 | 0.90 | CTSK (0.42) | CTSKNAMPTTP53SMN1; SMN2 | |
| SCHEMBL4040494 | 0.89 | CTSK (0.39) | CTSKSMYD3ACEGPR132 | |
| SCHEMBL4041827 | 0.89 | CTSK (0.43) | CTSKSMYD3ACEGPR132 | |
| SCHEMBL4045831 | 0.89 | CTSK (0.51) | CTSKSMYD3SMN1; SMN2ACEMAPT | |
| SCHEMBL4040030 | 0.88 | CTSK (0.41) | CTSKTP53SMN1; SMN2MAPT | |
| SCHEMBL4038224 | 0.88 | CTSK (0.44) | CTSKSMYD3ACEGPR132 | |
| SCHEMBL4042752 | 0.88 | CTSK (0.52) | CTSKSMYD3ACEGPR132 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885NAMPT 1027/4885SMYD3 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.